Search results for "sirolimus"

showing 10 items of 98 documents

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

2012

Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence, prognosis of the disease has fortunately improved. We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL. At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results. In addition, with a brief outline of other treatment options, we aim to g…

Oncologymedicine.medical_specialtybusiness.industryFirst linemantle cell lymphomaCancerTreatment optionsmTOR-inhibitorReviewDiseasemedicine.diseaseBioinformaticslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282TemsirolimusClinical knowledgeOncologyInternal medicinetemsirolimusmedicineRefractory Mantle Cell LymphomaMantle cell lymphomabusinessmedicine.drugClinical Medicine Insights: Oncology
researchProduct

Chronically elevated branched chain amino acid levels are pro-arrhythmic.

2022

Aim. Cardiac arrhythmias comprise a major health and economic burden and are associated with significant morbidity and mortality, including cardiac failure, stroke and sudden cardiac death (SCD). Development of efficient preventive and therapeutic strategies is hampered by incomplete knowledge of disease mechanisms and pathways. Our aim is to identify novel mechanisms underlying cardiac arrhythmia and SCD using an unbiased approach. Methods and Results. We employed a phenotype-driven N-ethyl-N-nitrosourea (ENU) mutagenesis screen and identified a mouse line with a high incidence of sudden death at young age (6-9 weeks) in the absence of prior symptoms. Affected mice were found to be homozyg…

0301 basic medicinemedicine.medical_specialtyPhysiologyBranched-chain amino acid030204 cardiovascular system & hematologySudden deathSudden cardiac deathAfterdepolarization03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicinePhysiology (medical)Internal medicineCardiac conductionmedicineAnimalsHumansMyocytes CardiacBCAAArrhythmia ; Bcaa ; Electrophysiology ; Metabolism ; Sudden DeathHeart FailureSirolimusbusiness.industrySudden deathCardiac arrhythmiamedicine.diseaseElectrophysiology030104 developmental biologyEndocrinologyMetabolismchemistryHeart failureCalciumMetabolic syndromeCardiology and Cardiovascular MedicinebusinessArrhythmiaAmino Acids Branched-ChainCardiovascular research
researchProduct

L’uso di stent con sirolimus e’ significativamente associate alla riduzione della mortalita’ totale e della morbidita’ cardiovascolare sia a 6 mesi c…

2006

stent sirolimus eventi cardiovascolari
researchProduct

Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling.

2009

Cognitive impairment is one of the most important negative consequences associated with cannabis consumption. We found that CB1 cannabinoid receptor (CB1R) activation transiently modulated the mammalian target of rapamycin (mTOR)/p70S6K pathway and the protein synthesis machinery in the mouse hippocampus, which correlated with the amnesic properties of delta9-tetrahydrocannabinol (THC). In addition, non-amnesic doses of either the mTOR blocker rapamycin or the protein synthesis inhibitor anisomycin abrogated the amnesic-like effects of THC, pointing to a mechanism involving new protein synthesis. Moreover, using pharmacological and genetic tools, we found that THC long-term memory deficits …

MaleCannabinoid receptormedicine.medical_treatmentGlutamic AcidHippocampusReceptors N-Methyl-D-AspartateGlutamatergicchemistry.chemical_compoundMiceCognitionReceptor Cannabinoid CB1Memorymental disordersmedicineAnimalsDronabinolPI3K/AKT/mTOR pathwayAnisomycingamma-Aminobutyric AcidMice KnockoutNeuronsProtein Synthesis InhibitorsSirolimusMemory DisordersChemistryGeneral NeuroscienceTOR Serine-Threonine KinasesRibosomal Protein S6 Kinases 70-kDanervous systemKnockout mouseNMDA receptorPhosphorylationCannabinoidNeuroscienceProtein KinasesAnisomycinCentral Nervous System AgentsSignal TransductionNature neuroscience
researchProduct

mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA

2013

Abstract Vaccination with in vitro transcribed RNA encoding tumor antigens is an emerging approach in cancer immunotherapy. Attempting to further improve RNA vaccine efficacy, we have explored combining RNA with immunomodulators such as rapamycin. Rapamycin, the inhibitor of mTOR, was used originally for immunosuppression. Recent reports in mouse systems, however, suggest that mTOR inhibition may enhance the formation and differentiation of the memory CD8+ T-cell pool. Because memory T-cell formation is critical to the outcome of vaccination aproaches, we studied the impact of rapamycin on the in vivo primed RNA vaccine-induced immune response using the chicken ovalbumin-expressing B16 mela…

Cancer Researchmedicine.medical_treatmentImmunologyMelanoma ExperimentalCD8-Positive T-LymphocytesBiologyCancer VaccinesLymphocytes Tumor-InfiltratingImmune systemAntigenCancer immunotherapyAntigens NeoplasmIn vivomedicineAnimalsRNA NeoplasmPI3K/AKT/mTOR pathwaySirolimusVaccines SyntheticAntibiotics AntineoplasticTOR Serine-Threonine KinasesVaccinationRNACell DifferentiationCombined Modality TherapyMice Inbred C57BLVaccinationImmunologyCancer researchFemaleDrug Screening Assays AntitumorImmunologic MemoryCD8Cancer Immunology Research
researchProduct

IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED,…

2017

OncologyCancer Researchmedicine.medical_specialtybusiness.industryHematologyGeneral Medicinemedicine.diseaseTemsirolimus03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisInternal medicineIbrutinibMedicineMantle cell lymphomaOpen labelbusinessPreviously treated030215 immunologymedicine.drugHematological Oncology
researchProduct

Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease.

2009

Objective: To investigate long-term outcomes of unprotected left main coronary artery (ULMCA) disease treatment using drug-eluting stents (DES). Background: In several studies, DES implantation in ULMCA appeared safe and effective at mid-term; however, to date, there is limited long-term data. Methods: All consecutive patients undergoing sirolimus- or paclitaxel-eluting stent implantation in ULMCA disease at a single institution were evaluated. The primary endpoint was long-term major adverse cardiac events (MACE) defined as cardiac death, nonfatal myocardial infarction, or target lesion revascularization (TLR). Stent thrombosis (ST), according to Academic Research Consortium definitions, w…

Malemedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentCoronary Artery DiseaseCoronary AngiographyRestenosisRecurrenceInternal medicineLong-term outcomes.medicineClinical endpointHumansRadiology Nuclear Medicine and imagingcardiovascular diseasesMyocardial infarctionSurvival rateAgedProportional Hazards ModelsSirolimusChi-Square Distributionbusiness.industryHazard ratioEuroSCOREDrug-Eluting StentsGeneral MedicineLeft main coronary arterymedicine.diseaseSurgeryTreatment OutcomeDrug-eluting stentCardiologyFemaleDrug-eluting stentCardiology and Cardiovascular MedicinebusinessMaceFollow-Up StudiesCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions
researchProduct

Initial experience with the novel BioMime 60 mm-long sirolimus-eluting tapered stent system in long coronary lesions

2017

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyProsthesis Design03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineRisk FactorsmedicineHumansProspective Studies030212 general & internal medicineNon-ST Elevated Myocardial InfarctionAgedSirolimusbusiness.industryStentCardiovascular AgentsDrug-Eluting StentsMiddle AgedSurgeryTreatment OutcomeSirolimusFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEuroIntervention
researchProduct

Checkpoint adaptation in recombination-deficient cells drives aneuploidy and resistance to genotoxic agents.

2020

Abstract Human cancers frequently harbour mutations in DNA repair genes, rendering the use of DNA damaging agents as an effective therapeutic intervention. As therapy-resistant cells often arise, it is important to better understand the molecular pathways that drive resistance in order to facilitate the eventual targeting of such processes. We employ recombination-defective diploid yeast as a model to demonstrate that, in response to genotoxic challenges, nearly all cells eventually undergo checkpoint adaptation, resulting in the generation of aneuploid cells with whole chromosome losses that have acquired resistance to the initial genotoxic challenge. We demonstrate that adaptation inhibit…

Genome instabilitySaccharomyces cerevisiae ProteinsDNA RepairDNA repairAneuploidySaccharomyces cerevisiaeBiologyBiochemistryGenomic Instabilitychemistry.chemical_compoundGene Knockout TechniquesDrug Resistance FungalmedicineCytotoxicityMolecular BiologyRecombination GeneticSirolimusCell BiologyCell Cycle Checkpointsmedicine.diseaseAneuploidyPhenotypeDiploidyCell biologyRad52 DNA Repair and Recombination ProteinchemistryAdaptationPloidyDNADNA repair
researchProduct

Longevity-related molecular pathways are subject to midlife “switch” in humans

2019

Emerging evidence indicates that molecular aging may follow nonlinear or discontinuous trajectories. Whether this occurs in human neuromuscular tissue, particularly for the noncoding transcriptome, and independent of metabolic and aerobic capacities, is unknown. Applying our novel RNA method to quantify tissue coding and long noncoding RNA (lncRNA), we identified ~800 transcripts tracking with age up to ~60 years in human muscle and brain. In silico analysis demonstrated that this temporary linear “signature” was regulated by drugs, which reduce mortality or extend life span in model organisms, including 24 inhibitors of the IGF‐1/PI3K/mTOR pathway that mimicked, and 5 activators that oppos…

0301 basic medicineAgingved/biology.organism_classification_rank.speciesMuscle Fibers SkeletallihaksetTranscriptome0302 clinical medicineGene expressionGene Regulatory NetworksRNA-Seqmedia_commonCerebral CortexNeuronsreactive oxygen speciesihoTOR Serine-Threonine Kinasesmitochondrial complex 1LongevityBrainNon-coding RNAAlzheimer'sECSITCell biologytranskriptio (biologia)mTORRNA Long NoncodingOriginal ArticleaivotSignal TransductionAdultTranscriptional ActivationskinIn silicomedia_common.quotation_subjectLongevityBiology03 medical and health sciencesHumanslong noncoding RNAskeletal muscleModel organismGeneSirolimusved/biologyagingRNACell BiologyTwins MonozygoticOriginal Articles030104 developmental biologyikääntyminenRNATranscriptome030217 neurology & neurosurgery
researchProduct